Russian pharmaceutical manufacturers stake on prescription products

Print 03 July 2018
GMP News

In the first five months of 2018, Russia produced medicinal products worth 132.2 billion rubles (in ex works prices). Compared to the same period of the last year, the dynamics are still negative.

Even despite a relatively active period in May, the total output in ruble-denominated terms declined by 2.3%. In physical terms, the figures are noticeably worse. In January-May 2018, Russian companies manufactured only 1.63 billion packages, which is 12% less than over the same period last year.

Still, the decline of shipments mostly affects non-prescription products. In this case, the long-term dynamics shows a decline of 13% in terms packages, while the shipments of Rx products decreased by 11%. At the same time, the dynamics is not as disastrous when calculated in minimum dosage units. In this case, we observed a decline of 9% for OTC products. Moreover, the dynamics for Rx products turned out to be even positive (+8.5%), as there was a significant change in the minimum dosage units used for packages supplied to the market. In ruble-denominated terms, the growth rates reported for various categories also diverge radically. In the first 5 months of 2018, the manufacturing of OTC drugs dropped by 14% in monetary terms, while the output of prescription drugs showed positive dynamics and increased by 2%.

Among OTC drugs, the worst performers in physical terms have been the same EphMRA groups as a month ago, including systemic antiviral drugs (-31%), analgesics (-22%), anti-inflammatory and antitussive drugs (-18%).

For Rx products, worst dynamics in physical terms were reported for intravenous solutions (-43%), and anti-inflammatory and anti-rheumatic drugs (-24%).

Source

Return